HOUSTON and LEXINGTON, Mass.—February 3, 2017—Quanterix Corporation, a company digitizing biomarker analysis to advance the science of precision health, today announced that Kevin Hrusovsky, Quanterix Chief Executive Office
January 9, 2017
Investment in new products, menu and globalization coupled with 60 percent revenue growth positions Quanterix for a “breakout” 2017; CEO wins Healthcare Innovation All-Star Award
January 9. 2017
Amended licensing agreement with long-term partner allows Quanterix to continue innovation and commercialization within its expanding fields
January 5, 2017
Presenting for the second consecutive year, Quanterix will be kicking off the 2017 conference by highlighting the Company’s position to transform precision health
Quanterix to Unveil Groundbreaking Neurodegenerative Disease Research and Strategic Partnership at Neuroscience 2016
November 15, 2016
Researchers will present key findings on the development of sensitive predictive biomarkers to establish therapeutic strategies for neurodegenerative diseases; Company will join forces with UmanDiagnostics to provide an ultrasensitive assay for Nf-L
November 3, 2016
Following the Company's successful participation in the Powering Precision Health Summit, Quanterix is bringing its insights and innovations to the West Coast
October 18, 2016
Quanterix announces that it has been named the “Late Stage Leader” Buzz of BIO winner. As a winner of this award – which recognizes innovative companies that have raised more than $25 million as of July 1, 2016 – Quanterix will also be presenting at the 2016 BIO Investor Forum.
September 26, 2016
Quanterix announces that it is making a strategic investment in ImmunArray, a molecular diagnostics company advancing the development of novel, multi-marker tests for complex diseases with compelling levels of accuracy.
Quanterix and Illumina Founder to Present Novel Approach to Cancer Diagnostics at Powering Precision Health 2016
September 21, 2016
August 1, 2016
Quanterix announces a license agreement for research use with Banyan Biomarkers, a pioneering company in the development of biomarkers for traumatic brain injury (TBI).